PCRX
Pacira BioSciences, Inc.
25.10$
-1.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +13.8% | +15.4% | -46.8% | +174.8% | +44.3% | +9.2% | +63.2% | +15.6% | +6.5% | +22.5% | -19.7% | |
| – | +14.3% | +12.6% | +7.1% | -4.8% | +48.7% | +1.7% | +43.4% | +220.5% | -17.4% | +4.2% | +15.5% | |
| – | +34.4% | -6.4% | +1.1% | +0.4% | +6.1% | +18.6% | +5.8% | +13.8% | -0.4% | +6.8% | +12.4% | |
| – | +33.8% | -5.4% | +18.4% | -12.9% | +70.5% | -234.8% | – | +5.1% | – | – | – | |
| – | – | – | -111.6% | – | – | – | – | – | – | – | – | |
| – | +88.5% | -40.1% | -22.0% | -24.7% | -30.0% | +272.1% | +21.3% | -34.4% | -49.6% | -29.8% | +44.2% | |
| – | -83.0% | +205.2% | +262.3% | – | -724.5% | +116.1% | -92.5% | +983.1% | – | -207.4% | – | |
| – | – | – | – | – | – | -62.5% | +65.2% | – | – | – | – | |
| – | +39.1% | -42.7% | +17.5% | +5.8% | +18.1% | +433.9% | -93.8% | +5.1% | -103.6% | +23,484.9% | +493.3% | |
| – | +0.0% | -99.7% | – | -100.2% | +0.0% | – | +190.0% | -217.6% | -57.7% | – | -383.0% | |
| – | -91.0% | -32.1% | +2,987.2% | -96.0% | -59.0% | +5,957.3% | +71.2% | -205.5% | -54.4% | – | -2,228.8% | |
| – | -22.2% | -208.1% | – | +331.2% | -169.3% | – | +2,134.9% | -199.1% | – | +151.2% | -195.8% | |
| – | -442.8% | – | -116.9% | – | +75.7% | -35.0% | +103.5% | +44.3% | +21.1% | +28.1% | -23.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.